Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?

Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.

Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?

Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed at $36.50 in the latest trading session, marking a -0.63% move from the prior day.

Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up

Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.

Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study

Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.

Stock Market News for Jan 19, 2021

This week will be significant both politically and economically as President elect Joe Biden will formally take charge of the U.S. President on Jan 20.

Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug

Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.

Stock Market News for Jan 18, 2021

Wall Street closed lower on Friday on concerns regarding slow vaccination process and mixed economic data.

Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine

Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.

AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing

AstraZeneca's (AZN) four-week, fixed-dose regimen (1500 mg) of Imfinzi will reduce patients's medical visits by half, thereby improving patent convenience.

Pfizer's (PFE) Xalkori Gets FDA Nod for Rare Lymphoma in Kids

FDA approves Pfizer's (PFE) Xalkori for relapsed or refractory ALK-positive anaplastic large cell lymphoma, a rare form of non-Hodgkin lymphoma (NHL), in pediatric patients and young adults.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals

Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.

Exact Sciences (EXAS) Posts Solid Preliminary Q4 Testing Revenues

Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.

Why Pfizer (PFE) Could Beat Earnings Estimates Again

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sarepta (SRPT) Inks New Gene Editing Research Collaboration

Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $36.86, marking a -0.86% move from the previous day.

Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $37.18, moving -1.56% from the previous trading session.

Sweta Jaiswal, FRM headshot

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

COVID-19 Vaccine Production to Ramp Up

COVID-19 Vaccine Production to Ramp Up

Lilly's (LLY) Alzheimer's Drug Promising in Mid-Stage Study

Lilly (LLY) announces data from a phase II study on its Alzheimer's disease candidate, donanemab, which shows slowing of cognitive decline.

Mark Vickery headshot

Covid-19 Vaccinations Promise to Ramp Up

Guidance for the end of 2020 was to have 20 million Americans with the first half of the two-injection immunization treatment; as of now, only around 9 million Americans have received the first dose.

Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed the most recent trading day at $37.77, moving +1.72% from the previous trading session.

Sanghamitra Saha headshot

4 Reasons for Bank ETFs to Win in 2021

Bank ETFs should stay strong in the coming days on the back of cheaper valuation, Fed's signal for buybacks, Democrat's control over Senate and spike in bond yields.

Futures Down as Investors Weigh Covid-19 Cases Against Vaccines

Futures Down as Investors Weigh Covid-19 Cases Against Vaccines